News flow

Regulatory Press Releases

29 November 2021

Today #orexo looks forward to present at @aktiespararna Stora Aktiedagen. At 2 pm Nikolaj Sørensen CEO will give a… https://t.co/k9oRXZLJUe

26 November 2021

amorphOX™, is an inventive powder-based technology, that is very rapidly dissolving, stable & works with different… https://t.co/uuH4sJEwfT

26 November 2021

Today we are proud to inform about the amorphOX™ platform, our new proprietary drug delivery technology, which will… https://t.co/V0s2CTLGcQ

Europe

US

Lena Wange

IR & Corporate Communications Director

Switchboard: +46 (0)18 780 88 00

Direct phone: +46 73 064 16 36

Send email: ir@orexo.com

Location: Uppsala, Sweden

Dennis Urbaniak

EVP Digital Therapeutics

Switchboard: +1 (0)855 982 7658

Direct phone: +1 973 294 3183

Send email: us.media@orexo.com

Location: New Jersey, US